Nasal vaccines provide needle-free vaccination against various diseases such as influenza, diphtheria, cholera, whooping cough, meningitis, etc. Nasal vaccines deliver antigens directly to the nasal mucosa which induces a protective immune response at the site of pathogen entry.

The global nasal vaccines market is estimated to be valued at US$ 416.8 Mn or Mn in 2023 and is expected to exhibit a CAGR of 8.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
Increasing demand for needle-free vaccination is a major driver propelling the growth of the nasal vaccines market. Nasal vaccines help in avoiding the pain and medical risk associated with injections. This increases patient preference and compliance for nasal vaccines. For instance, according to a study published in 2019 in npj Vaccines, intranasal influenza vaccines were found to induce significantly higher antigen-specific T cells and B cells in nasal mucosa as compared to intramuscular flu shots. The higher mucosal immune response of nasal vaccines makes them more effective in preventing influenza transmission and infection.
Moreover, nasal vaccines help in inducing both systemic and mucosal immunity. Mucosal immunity provides early protection against respiratory pathogens at the primary site of infection. For instance, intranasal live attenuated influenza vaccines have been found to induce specific antibodies in nasal secretions that can neutralize influenza virus and prevent its replication. The induction of mucosal immunity makes nasal vaccines more advantageous over intramuscular injections. This is expected to accelerate the demand of nasal vaccines during the forecast period.

SWOT Analysis
Strength: The nasal vaccines market provides non-invasive route of administration to patients. Nasal vaccines elicit mucosal and systemic immune responses making them effective against respiratory infections. Nasal vaccines are needle-free and provide painless delivery which increases patient compliance.

Weakness: Developing efficient nasal adjuvant formulations remains a challenge for researchers. Limited stability and shelf life of nasal vaccines require cold chain management during transportation and storage. Clinical trial data demonstrating efficacy of nasal vaccines is still emerging.

Opportunity: The growing support from regulatory bodies to expedite development of effective nasal vaccines will boost market growth. Nasal vaccines offer an attractive alternative to current injection-based vaccines against influenza and COVID-19. Rising cases of respiratory diseases in developing nations present lucrative opportunities.

Threats: Strict regulations for vaccine development and approval acts as a roadblock. Established infrastructure for injection-based vaccines poses pricing challenges for novel nasal vaccines. Resistance from consumers accustomed to intramuscular vaccines hampers commercial adoption.

Key Takeaways
The Global Nasal Vaccines Market Size is expected to witness high growth. The market size is projected to reach US$ 1,048.2 Mn by 2030 growing at a CAGR of 8.6% during the forecast period of 2023 to 2030. Nasal vaccines offer significant advantages over intramuscular vaccines such as needle-free and painless delivery, induction of systemic as well as mucosal immunity.

Regional analysis: North America dominates the nasal vaccines market currently owing to substantial research investments, presence of key players and favorable regulations. Asia Pacific region is anticipated to grow at the fastest pace on account of rising incidence of respiratory infections, growing awareness and improving healthcare infrastructure in developing countries.

Key players: Key players operating in the nasal vaccines market are AstraZeneca, GlaxoSmithKline plc, Pfizer Inc., Serum Institute of India Pvt. Ltd., Sanofi Pasteur SA, Johnson & Johnson Services, Inc., Sinovac Biotech Ltd., Bharat Biotech International Limited, Altimmune, Inc., BiondVax Pharmaceuticals Ltd., FluGen Inc., Vaxart, Inc., Intravacc, Ennaid Therapeutics, LLC, Gamma Vaccines Pty Ltd. These players are involved in new product launches and strategic collaborations to strengthen their market position.

Get more insights on this topic:
https://www.rapidwebwire.com/nasal-vaccines-market-demand-size/